Relief of loperamide-induced constipation by peptidic and small molecule RXFP4 agonists in mice
文献类型:期刊论文
作者 | Yan, Shiyu1,2,4; Chen, Yan7,8; Wang, Jiang6; Wang, Qiuying5; Zhou, Qingtong7,8; Liu, Hong3![]() ![]() ![]() |
刊名 | BIOCHEMICAL PHARMACOLOGY
![]() |
出版日期 | 2025-07-01 |
卷号 | 237页码:12 |
关键词 | RXFP4 INSL5 Agonist Constipation Colonic motility |
ISSN号 | 0006-2952 |
DOI | 10.1016/j.bcp.2025.116924 |
英文摘要 | Constipation is a common gastrointestinal disorder often treated symptomatically as the existing therapies all have significant side-effects. The relaxin/insulin-like family peptide receptor 4 (RXFP4), a class A G protein-coupled receptor, has emerged as a potential drug target for this indication as it regulates intestinal motility. Here, we investigated the therapeutic effects of both peptidic (insulin-like peptide 5, INSL5) and small molecule (DC591053) RXFP4 agonists on loperamide-induced constipation in mice. Fecal water content, fecal weight, colonic transit time, and serum levels of neurotransmitters such as nitric oxide (NO), serotonin (5-HT), and vasoactive intestinal peptide (VIP) were assessed, in conjunction with the examination of colon tissue histology and expression levels of aquaporin 3 (AQP3), transient receptor potential vanilloid 1 (TRPV1), and calcitonin gene-related peptide (CGRP). It was found that both INSL5 and DC591053 dose-dependently increased fecal water content and weight, accelerated colonic transit, and improved colon morphology in constipated mice, accompanied by the altered expression levels of factors related to constipation. Comparative analysis revealed that while the two agonists produced similar beneficial outcomes, their different chemical nature may affect pharmacokinetics property and receptor engagement. Our results suggest that the activation of RXFP4 presents a novel approach to alleviating constipation. |
WOS关键词 | CELL-LINES ; COLON ; IDENTIFICATION ; EXPRESSION ; SEROTONIN ; INSL5 |
资助项目 | Strategic Priority Research Program of the Chinese Academy of Sciences[XDB1060402] ; National Key Basic Research Program of China[2023YFA1800804] ; National Key Basic Research Program of China[2021ZD0203400] ; Hainan Provincial Major Science and Technology Project[ZDKJ2021028] ; Program of Shanghai Academic/Technology Research Leader[23XD1400900] |
WOS研究方向 | Pharmacology & Pharmacy |
语种 | 英语 |
WOS记录号 | WOS:001469480400001 |
出版者 | PERGAMON-ELSEVIER SCIENCE LTD |
源URL | [http://119.78.100.183/handle/2S10ELR8/317491] ![]() |
专题 | 新药研究国家重点实验室 |
通讯作者 | Liu, Hong; Wang, Ming-Wei; Yang, Dehua |
作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Stake Key Lab Chem Biol, Shanghai 201203, Peoples R China 5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China 6.Lingang Lab, Shanghai 200031, Peoples R China 7.Shanghai Jiao Tong Univ, Res Ctr Med Struct Biol, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China 8.Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai 200032, Peoples R China 9.Res Ctr Deepsea Bioresources, Sanya 572025, Hainan, Peoples R China 10.Hainan Med Univ, Engn Res Ctr Trop Med Innovat & Transformat, Sch Pharm, Minist Educ, Haikou 570228, Peoples R China |
推荐引用方式 GB/T 7714 | Yan, Shiyu,Chen, Yan,Wang, Jiang,et al. Relief of loperamide-induced constipation by peptidic and small molecule RXFP4 agonists in mice[J]. BIOCHEMICAL PHARMACOLOGY,2025,237:12. |
APA | Yan, Shiyu.,Chen, Yan.,Wang, Jiang.,Wang, Qiuying.,Zhou, Qingtong.,...&Yang, Dehua.(2025).Relief of loperamide-induced constipation by peptidic and small molecule RXFP4 agonists in mice.BIOCHEMICAL PHARMACOLOGY,237,12. |
MLA | Yan, Shiyu,et al."Relief of loperamide-induced constipation by peptidic and small molecule RXFP4 agonists in mice".BIOCHEMICAL PHARMACOLOGY 237(2025):12. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。